This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Erectile dysfunction, exclusion
ERECTILE_EXCLUSION
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly males |
226754 |
2. Check conditionsNone |
226754 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
137 |
4. Check minimum number of eventsNone |
137 |
5. Include endpointsNone |
137 |
6. Filter based on genotype QC (FinnGen only) |
132 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- I27
- Name in latin
- Hypertensio pulmonalis primaria
Similar endpoints
↥List of similar endpoints to
Erectile dysfunction, exclusion
based on the number of shared cases.
Similar with more cases:
- Secondary right heart disease
- Other pulmonary heart/vessel disease
- Pulmonary heart disease, diseases of pulmonary circulation
- Cardiovascular diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 132 | - | 132 |
| Unadjusted period prevalence (%) | 0.06 | - | 0.06 |
| Median age at first event (years) | 66.43 | - | 66.43 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 137
- Matched controls
- 1370
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
128.0
102
*
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
129.4
48.8
50
6
G04BE03
ATC
sildenafil; oral
103.1
40.8
43
6
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
186.3
40.2
40
*
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
179.8
39.0
39
*
C03DA01
ATC
spironolactone; oral
9.8
38.0
60
101
4168X
ICD-9 Finland
Chronic pulmonary heart disease, Other chronic pulmonary heart diseases
+∞
33.7
31
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
10.9
33.5
43
55
C03CA01
ATC
furosemide; systemic
7.8
29.0
101
363
I27.8
ICD-10 Finland
Other specified pulmonary heart diseases
333.1
27.8
27
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
6.1
24.7
66
181
C02KX04
ATC
macitentan; oral
+∞
18.1
17
*
B01AA03
ATC
warfarin; systemic
4.7
17.9
66
227
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
4.6
17.8
67
234
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
6.8
16.9
30
54
C01AA05
ATC
digoxin; systemic
5.0
15.4
41
107
R06.0
ICD-10 Finland
Dyspnoea
4.2
15.3
63
230
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
15.1
50
155
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
6.5
14.7
27
50
4912B
ICD-9 Finland
Chronic bronchitis, Obstructive chronic bronchitis[BRONCHITIS OBSTRUCTIVA CUM EMPHYSEMATE]
16.0
14.3
23
17
J96.1
ICD-10 Finland
Chronic respiratory failure
17.2
14.1
22
15
C02KX01
ATC
bosentan; oral
+∞
13.8
13
*
AP2
HP
Catheterization of the right side of the heart
154.7
13.7
14
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
11.9
13.1
24
24
I50.9
ICD-10 Finland
Heart failure, unspecified
3.9
12.7
52
186
201
Kela drug reimbursment
Chronic cardiac insufficiency
5.1
12.5
30
71
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.7
12.1
56
216
H02AB06
ATC
prednisolone; systemic
3.5
11.8
84
424
G04BE08
ATC
tadalafil; oral
71.2
11.8
13
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
11.7
82
410
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.3
11.1
20
36
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
12.0
10.7
19
18
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
20.8
10.5
15
8
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
12.8
10.4
18
16
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.6
10.2
21
43
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
9.9
47
181
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
8.7
9.9
21
28
WX740
NOMESCO Finland
Nitrogen oxide therapy
107.1
9.5
10
*
XF620
NOMESCO Finland
Examination of circulation with color method
107.1
9.5
10
*
205
Kela drug reimbursment
Chronic hypertension
3.1
9.3
59
270
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
4.5
9.2
25
65
I50.0
ICD-10 Finland
Congestive heart failure
4.0
8.8
29
87
XF622
NOMESCO Finland
Measurement of minute volume of heart
53.5
8.8
10
*
4289X
ICD-9 Finland
Heart failure, unspecified
17.8
8.7
13
8
GD2SN
NOMESCO Finland
Lung ventilation SPECT
95.7
8.5
9
*
C02KX05
ATC
riociguat; oral
+∞
8.4
8
*
B01AC27
ATC
selexipag; oral
+∞
8.4
8
*
XF614
NOMESCO Finland
Measurement of pulmonary artery pressure
+∞
8.4
8
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.8
8.3
20
47
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.4
8.0
15
16
R28
ICPC
Limited function/disability (R)
26.7
7.7
10
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.9
7.5
24
70
GD1UN
NOMESCO Finland
Lung circulation SPECT
84.5
7.5
8
*
A46
ICD-10 Finland
Erysipelas
3.2
7.4
34
127
FB1BC
NOMESCO Finland
Extensive angiography of arteria pulmonalis
+∞
7.4
7
*
C02KX02
ATC
ambrisentan; oral
+∞
7.4
7
*
383
Kela drug reimbursment
Selexipag
+∞
7.4
7
*
M04AA01
ATC
allopurinol; systemic
3.1
7.3
38
152
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
17.8
6.9
10
6
R03AC02
ATC
salbutamol; inhalant
2.6
6.8
78
465
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
9.4
6.7
13
15
WX872
NOMESCO Finland
Intensive care
5.8
6.6
18
35
R4110
NOMESCO Finland
Physiotherapy
2.7
6.5
46
216
ZXE30
NOMESCO Finland
More than five and less than seven hours
5.6
6.5
18
36
Z2221
NOMESCO Finland
Medical doctor
2.7
6.5
43
196
R03BB01
ATC
ipratropium bromide; inhalant
3.9
6.4
20
57
A12BA01
ATC
potassium chloride; oral
4.4
6.4
17
43
ZX120
NOMESCO Finland
Intravenous
3.5
6.3
24
79
JN4AD
NOMESCO Finland
Body CT examination
3.9
6.3
20
58
XF400
NOMESCO Finland
ECG with 12 standard connections
2.8
6.3
40
178
Z3226
NOMESCO Finland
Physiotherapist
2.9
6.2
34
139
AN1
HP
Coronary angiography
3.1
6.0
28
104
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
140
5.05
17.48
5.0
2.3
17.35
23.49
%
2.31
43
126
50
146
4.82
16.50
5.0
2.3
2.48
2.26
g/l
1.96
50
134
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
34
7.93
15.38
9.0
2.4
0.32
0.30
u/ml
0.12
18
19
18
9
22.75
12.85
1.4
1.4
—
—
—
0
0
41
123
4.33
12.75
16.6
12.8
1.36
0.51
mmol/l
0.40
28
103
30
91
3.94
8.98
2.8
2.8
0.19
0.22
g/l
1.08
30
82
26
77
3.93
8.00
24.5
9.4
25.29
24.33
mmol/l
0.44
26
77
31
107
3.45
7.61
8.8
5.6
2.16
0.83
mmol/l
0.84
26
75
33
123
3.22
7.15
2.9
1.8
—
—
—
0
0
61
323
2.60
6.85
9.6
3.2
28.59
35.09
u/l
1.68
61
309
42
185
2.83
6.76
17.8
1.6
1.82
2.27
mg/l
0.31
33
151
30
109
3.24
6.75
9.1
5.6
5.96
5.62
kpa
0.81
30
102
11
9
13.15
6.71
3.0
3.1
—
—
—
0
0
78
469
2.54
6.64
48.2
15.6
1.74
1.35
inr
2.32
24
132
32
126
3.01
6.27
3.1
1.9
—
—
—
0
0
77
473
2.43
6.09
21.3
6.8
15.51
12.58
umol/l
1.39
77
458
27
101
3.08
5.75
1.1
1.2
39.14
33.31
iu/ml
—
7
30
11
13
9.08
5.67
11.2
10.8
11.47
9.49
mg/l
0.66
11
13
15
32
5.13
5.17
2.5
2.8
—
—
—
0
0
64
385
2.24
5.05
6.8
4.2
321.05
57.74
ng/l
0.42
55
281
12
21
6.15
4.88
2.8
1.3
—
—
—
0
0
35
166
2.49
4.72
3.1
1.9
—
—
—
0
0
8
8
10.52
4.58
1.0
1.0
—
—
—
0
0
11
21
5.60
4.24
2.1
1.9
—
—
—
0
0
20
78
2.83
3.93
2.4
1.5
—
—
—
0
0
9
15
6.34
3.88
1.1
1.5
—
—
—
0
0
14
40
3.78
3.74
1.3
1.5
—
—
—
0
0
76
536
1.94
3.54
14.3
10.1
4.79
4.29
e9/l
0.81
69
465
65
439
1.91
3.41
21.4
9.0
1.17
1.20
mmol/l
2.13
56
383
61
404
1.92
3.39
19.2
7.9
1.16
1.20
mmol/l
3.39
55
371
16
61
2.84
3.27
2.6
1.5
—
—
—
0
0
11
30
3.89
3.16
2.2
1.3
—
—
—
0
0
6
8
7.78
3.08
2.0
1.5
187.33
275.38
u/l
—
6
8
5
5
10.31
3.00
1.4
1.4
—
—
—
0
0
5
5
10.31
3.00
1.4
1.4
96.60
75.80
%
—
5
5
21
97
2.38
2.95
8.0
4.4
4.89
4.53
kpa
0.41
21
89
14
56
2.67
2.62
9.4
3.9
24.81
24.88
mmol/l
0.04
14
56
6
12
5.17
2.43
4.2
3.8
55.50
53.67
%
—
6
12
6
12
5.17
2.43
2.5
1.5
—
—
—
0
0
5
9
5.72
2.23
1.4
1.2
6.20
9.78
u/l
—
5
9
8
25
3.33
2.13
1.5
1.4
—
—
—
0
0
8
26
3.20
2.05
3.5
1.6
—
—
—
0
0
7
21
3.45
1.99
1.6
1.2
—
—
—
0
0
7
21
3.45
1.99
1.0
1.0
—
—
—
0
0
5
11
4.67
1.96
1.0
1.3
—
—
—
0
0
40
269
1.69
1.95
3.8
2.3
143.50
291.45
u/l
1.31
40
254
6
151
0.37
1.91
2.2
2.0
9.44
14.04
nmol/l
—
6
141
7
23
3.15
1.82
2.6
1.3
—
—
—
0
0
38
522
0.62
1.67
3.6
4.6
18.68
21.30
%
0.74
17
250
5
14
3.66
1.63
2.2
1.9
—
—
—
0
0
7
26
2.78
1.60
3.9
1.6
—
—
—
0
0
6
20
3.09
1.60
3.0
1.7
—
—
—
0
0
6
20
3.09
1.60
3.0
1.7
—
—
—
0
0
6
20
3.09
1.60
2.7
1.3
—
—
—
0
0
5
15
3.42
1.53
3.8
1.2
—
—
—
0
0
5
15
3.42
1.53
3.4
1.3
—
—
—
0
0
5
15
3.42
1.53
3.4
1.3
—
—
—
0
0
39
276
1.58
1.53
4.9
2.9
0.25
0.38
e6/l
0.51
33
211
6
21
2.94
1.52
1.0
1.4
—
—
—
0
0
6
21
2.94
1.52
1.0
1.4
—
—
—
0
0
5
16
3.20
1.45
2.2
1.8
—
—
—
0
0
5
17
3.01
1.37
2.4
3.4
—
—
—
0
0
47
355
1.49
1.36
4.5
3.1
—
—
—
0
0
0
41
0.00
1.33
0.0
1.6
—
242.89
—
0
36
89
1004
0.68
1.32
71.1
23.2
39.82
40.84
%
0.58
84
945
5
18
2.84
1.29
4.4
1.7
—
—
—
0
0
5
20
2.55
1.16
1.2
1.3
—
—
—
0
0
5
20
2.55
1.16
1.2
1.2
201.80
221.00
u/ml
—
5
7
16
97
1.74
1.12
3.9
3.0
—
—
—
0
0
22
147
1.59
1.09
27.6
8.5
103.59
103.95
mmol/l
0.08
22
147
29
389
0.68
1.05
2.5
3.1
0.61
0.78
ug/l
1.04
19
256
5
22
2.32
1.04
1.0
1.2
—
—
—
0
0
54
646
0.73
1.00
4.2
5.1
2.11
2.84
ug/l
0.44
48
576
30
221
1.46
0.97
1.9
1.7
14.76
18.64
nmol/l
1.14
25
195
14
87
1.68
0.91
1.1
1.3
64.48
13.61
u/ml
—
6
29
24
171
1.49
0.91
3.3
2.8
0.42
0.47
e6/l
0.07
12
98
5
24
2.12
0.75
1.2
1.2
—
—
—
0
0
75
834
0.78
0.72
4.6
4.7
6.17
6.17
mmol/l
0.00
68
756
41
337
1.31
0.69
2.4
2.0
73.24
87.47
pmol/l
2.04
28
201
23
174
1.39
0.65
3.2
2.7
0.30
0.65
e6/l
0.59
11
99
10
64
1.61
0.60
3.7
1.8
—
—
—
0
0
49
422
1.25
0.57
6.2
4.6
0.00
0.00
estimate
-0.00
17
79
50
434
1.24
0.54
4.6
3.4
0.00
0.00
estimate
-0.00
17
75
49
427
1.23
0.50
4.7
3.4
0.00
0.01
estimate
0.49
17
86
8
118
0.66
0.48
1.5
1.4
—
—
—
0
0
44
382
1.22
0.47
5.2
3.0
—
—
—
0
0
28
232
1.26
0.44
5.0
3.7
0.00
0.01
estimate
0.49
16
72
5
33
1.53
0.42
2.4
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
203.98
—
0
15
38
334
1.19
0.35
4.8
3.7
—
—
—
0
0
23
194
1.22
0.32
1.7
1.9
314.69
387.90
pmol/l
0.93
18
168
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
31
285
1.11
0.16
4.5
4.0
5.41
11.40
mg/mmol
1.11
25
202
23
210
1.11
0.13
4.4
2.8
—
—
—
0
0
10
89
1.13
0.07
11.8
9.2
—
—
—
0
0
53
514
1.05
0.07
3.3
3.0
—
—
—
0
0
17
159
1.08
0.05
3.4
3.1
2.44
2.45
mmol/l
0.10
12
139
81
813
0.99
0.00
42.9
14.9
72.61
79.36
ml/min/173m2
1.61
74
677
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
35.80
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
10.66
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
7.74
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
12.71
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
7.56
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ERECTILE_EXCLUSION – Erectile dysfunction, exclusion
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).